Zentalis Pharmaceuticals Files 8-K
Ticker: ZNTL · Form: 8-K · Filed: Apr 28, 2025 · CIK: 1725160
| Field | Detail |
|---|---|
| Company | Zentalis Pharmaceuticals, Inc. (ZNTL) |
| Form Type | 8-K |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
TL;DR
Zentalis filed an 8-K, likely containing regulatory updates and financial info.
AI Summary
Zentalis Pharmaceuticals, Inc. filed an 8-K on April 28, 2025, reporting on events as of April 27, 2025. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates Zentalis Pharmaceuticals is providing updates or disclosures required by the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific material events or financial data that would indicate a high-risk situation.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Registrant
- 0001725160-25-000082 (other) — Accession Number
- 20250428 (date) — Filing Date
- 20250427 (date) — Report Date
FAQ
What is the primary purpose of this 8-K filing?
The filing is for Regulation FD Disclosure and Financial Statements and Exhibits, as indicated by the Item Information.
What is the exact name of the company filing this report?
The exact name of the registrant is Zentalis Pharmaceuticals, Inc.
On what date was this 8-K filed with the SEC?
The filing was made on April 28, 2025.
What is the state of incorporation for Zentalis Pharmaceuticals, Inc.?
Zentalis Pharmaceuticals, Inc. is incorporated in Delaware.
What is the SIC code for Zentalis Pharmaceuticals, Inc.?
The Standard Industrial Classification code for Zentalis Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2025 regarding Zentalis Pharmaceuticals, Inc. (ZNTL).